EP2320923A4 - Truncated analogues of glucose-dependent insulinotropic polypeptide - Google Patents

Truncated analogues of glucose-dependent insulinotropic polypeptide

Info

Publication number
EP2320923A4
EP2320923A4 EP09805288A EP09805288A EP2320923A4 EP 2320923 A4 EP2320923 A4 EP 2320923A4 EP 09805288 A EP09805288 A EP 09805288A EP 09805288 A EP09805288 A EP 09805288A EP 2320923 A4 EP2320923 A4 EP 2320923A4
Authority
EP
European Patent Office
Prior art keywords
glucose
dependent insulinotropic
insulinotropic polypeptide
truncated analogues
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09805288A
Other languages
German (de)
French (fr)
Other versions
EP2320923A2 (en
EP2320923B1 (en
Inventor
Zheng Xin Dong
Yeelana Shen
Daniel B Deoliveira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Priority to EP14194038.7A priority Critical patent/EP2915538A3/en
Priority to PL09805288T priority patent/PL2320923T3/en
Publication of EP2320923A2 publication Critical patent/EP2320923A2/en
Publication of EP2320923A4 publication Critical patent/EP2320923A4/en
Application granted granted Critical
Publication of EP2320923B1 publication Critical patent/EP2320923B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP09805288.9A 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide Active EP2320923B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14194038.7A EP2915538A3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide
PL09805288T PL2320923T3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18819208P 2008-08-07 2008-08-07
US20062808P 2008-12-02 2008-12-02
PCT/US2009/004543 WO2010016935A2 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP14194038.7A Division EP2915538A3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide
EP14194038.7A Division-Into EP2915538A3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Publications (3)

Publication Number Publication Date
EP2320923A2 EP2320923A2 (en) 2011-05-18
EP2320923A4 true EP2320923A4 (en) 2012-07-18
EP2320923B1 EP2320923B1 (en) 2014-12-24

Family

ID=41664127

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09805288.9A Active EP2320923B1 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide
EP14194038.7A Withdrawn EP2915538A3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14194038.7A Withdrawn EP2915538A3 (en) 2008-08-07 2009-08-07 Truncated analogues of glucose-dependent insulinotropic polypeptide

Country Status (16)

Country Link
US (1) US8450266B2 (en)
EP (2) EP2320923B1 (en)
JP (2) JP2011530506A (en)
KR (2) KR20110043687A (en)
CN (2) CN102170896A (en)
AU (1) AU2009280012B2 (en)
BR (1) BRPI0917001A2 (en)
CA (1) CA2733005C (en)
DK (1) DK2320923T3 (en)
EA (1) EA020018B1 (en)
ES (1) ES2528599T3 (en)
HK (2) HK1154787A1 (en)
MX (1) MX2011001028A (en)
PL (1) PL2320923T3 (en)
PT (1) PT2320923E (en)
WO (1) WO2010016935A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320923B1 (en) 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
CN102171244B (en) 2008-08-07 2015-05-13 益普生制药股份有限公司 Analogues of glucose-dependent insulinotropic polypeptide
US9072703B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
ES2537623T3 (en) 2009-08-10 2015-06-10 Ucl Business Plc Reversible covalent bond of functional molecules
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US20140377171A1 (en) * 2011-06-10 2014-12-25 Jean Claude Reubi Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof
JP5914641B2 (en) * 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Glucose-dependent insulinotropic polypeptide analogs, pharmaceutical compositions and uses thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3530671A3 (en) 2014-09-05 2019-11-13 University of Copenhagen Gip peptide analogues
SG11201805255TA (en) 2015-12-23 2018-07-30 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
CA3064510A1 (en) 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues
CA3097939A1 (en) 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103390A2 (en) * 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6905550B2 (en) 1996-05-06 2005-06-14 Princeton Trade & Technology, Inc. Method of removing organic materials using aqueous cleaning solutions
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
IL137388A (en) 1998-01-29 2005-05-17 Poly Med Inc Absorbable microparticles
WO2000004916A1 (en) 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
EP2322545A1 (en) 1998-12-07 2011-05-18 Ipsen Pharma Analogues of GLP-1
CA2367856C (en) 1999-03-29 2013-10-15 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US20040048248A1 (en) 1999-10-05 2004-03-11 Prayaga Sudhirdas K. Endozepine-like polypeptides and polynucleotides encoding same
EP1392484B1 (en) * 2001-04-06 2013-06-12 California Institute Of Technology High throughput screening of crystalization of materials
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
ES2239246T3 (en) * 2001-08-31 2005-09-16 Avidex Limited SOLUBLE RECEIVER OF CELLS T.
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003105760A2 (en) * 2002-06-15 2003-12-24 Enteromed, Inc. Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip)
MXPA05007163A (en) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Maleamic acid polymer derivatives and their bioconjugates.
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20090286724A1 (en) * 2005-10-26 2009-11-19 Chugai Seiyaku Kabushiki Kaisha Aggregable glp-1 analogue and sustained-release pharmaceutical composition
JP5399244B2 (en) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー DPP-IV resistant GIP hybrid polypeptide with selectable properties
EP2320923B1 (en) 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103390A2 (en) * 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREEN B D ET AL: "STRUCTURALLY MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) AS FUTURE ANTIDIABETIC AGENTS", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 10, no. 29, 1 January 2004 (2004-01-01), pages 3651 - 3662, XP009068381, ISSN: 1381-6128, DOI: 10.2174/1381612043382774 *
See also references of WO2010016935A2 *

Also Published As

Publication number Publication date
EA201170302A1 (en) 2011-10-31
JP2011530506A (en) 2011-12-22
CA2733005A1 (en) 2010-02-11
HK1209344A1 (en) 2016-04-01
EP2915538A2 (en) 2015-09-09
EP2320923A2 (en) 2011-05-18
HK1154787A1 (en) 2012-05-04
KR101419332B1 (en) 2014-07-15
WO2010016935A2 (en) 2010-02-11
US8450266B2 (en) 2013-05-28
EP2915538A3 (en) 2015-10-14
EA020018B1 (en) 2014-08-29
PT2320923E (en) 2015-02-24
DK2320923T3 (en) 2015-03-02
PL2320923T3 (en) 2015-06-30
JP5864506B2 (en) 2016-02-17
BRPI0917001A2 (en) 2016-02-16
EP2320923B1 (en) 2014-12-24
KR20110043687A (en) 2011-04-27
CN104031140A (en) 2014-09-10
US20110136724A1 (en) 2011-06-09
AU2009280012B2 (en) 2012-12-06
CN104031140B (en) 2017-04-12
KR20130093693A (en) 2013-08-22
WO2010016935A3 (en) 2010-04-08
CN102170896A (en) 2011-08-31
MX2011001028A (en) 2011-04-26
JP2014051505A (en) 2014-03-20
AU2009280012A1 (en) 2010-02-11
ES2528599T3 (en) 2015-02-10
CA2733005C (en) 2016-09-27

Similar Documents

Publication Publication Date Title
EP2328922A4 (en) Analogues of glucose-dependent insulinotropic polypeptide
HK1209344A1 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
HK1154790A1 (en) Glucose-dependent insulinotropic polypeptide analogues
EP2318433A4 (en) Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
HK1203531A1 (en) Glucagon analogues
IL218751A0 (en) Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
ZA201104592B (en) Glucagon analogues
ZA201104593B (en) Glucagon analogues
ZA201104591B (en) Glucagon analogues
EP2479193A4 (en) Homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof
HK1170941A1 (en) Oxyntomodulin peptide analogue
HK1170943A1 (en) Oxyntomodulin peptide analogue
EP2348049A4 (en) Novel application of aimp1 polypeptide
ZA201201259B (en) Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
GB0917072D0 (en) Peptide analogues of glucagon for diabetes therapy
EP2480578A4 (en) Polypeptide modification
HK1220701A1 (en) Insulin like peptides
EP2270141A4 (en) Partial peptide of lacritin
ZA201007911B (en) Processes for refolding of insulin
EP2478010A4 (en) Partial peptide of lacritin
HK1156630A1 (en) Schweinfurthin analogues schweinfurthin
GB0913228D0 (en) Loading element
EP2450036A4 (en) Surface anesthetic agent
GB0821979D0 (en) Use of variant interferon alpha
GB0903988D0 (en) Loading aid attachment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154787

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20120614

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101AFI20120608BHEP

17Q First examination report despatched

Effective date: 20130306

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140717

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 702779

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150115

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2528599

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150210

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009028590

Country of ref document: DE

Effective date: 20150212

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150217

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150227

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150400423

Country of ref document: GR

Effective date: 20150318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20141224

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150424

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009028590

Country of ref document: DE

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1154787

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E024300

Country of ref document: HU

26N No opposition filed

Effective date: 20150925

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 702779

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150807

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20160812

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20160712

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20170629

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20170626

Year of fee payment: 9

Ref country code: PL

Payment date: 20170614

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20170814

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170714

Year of fee payment: 9

Ref country code: GR

Payment date: 20170711

Year of fee payment: 9

Ref country code: DE

Payment date: 20170801

Year of fee payment: 9

Ref country code: FI

Payment date: 20170809

Year of fee payment: 9

Ref country code: GB

Payment date: 20170802

Year of fee payment: 9

Ref country code: NO

Payment date: 20170810

Year of fee payment: 9

Ref country code: CZ

Payment date: 20170714

Year of fee payment: 9

Ref country code: IT

Payment date: 20170824

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20170803

Year of fee payment: 9

Ref country code: TR

Payment date: 20170721

Year of fee payment: 9

Ref country code: IE

Payment date: 20170809

Year of fee payment: 9

Ref country code: AT

Payment date: 20170725

Year of fee payment: 9

Ref country code: DK

Payment date: 20170810

Year of fee payment: 9

Ref country code: SE

Payment date: 20170810

Year of fee payment: 9

Ref country code: HU

Payment date: 20170710

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141224

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170808

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009028590

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20180831

Ref country code: NO

Ref legal event code: MMEP

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180901

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 702779

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180807

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180808

REG Reference to a national code

Ref country code: BE

Ref legal event code: FP

Effective date: 20150312

Ref country code: BE

Ref legal event code: MM

Effective date: 20180831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190207

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190307

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190301

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807